QOL studies in epilepsy - worthwhile pursuit or waste of time? Ian Mundell Newsletter Article 15 February 2013 Pages: 3 - 4
Towards controlling that ‘old foe’, TB Theresa Szeto Newsletter Article 15 February 2013 Pages: 5 - 5
Responding to the squeeze on R&D budgets Robert Short Newsletter Article 15 February 2013 Pages: 7 - 7
Better thrombolysis by beating the endogenous problem Newsletter Article 15 February 2013 Pages: 9 - 9
L-735 524 - started with a bang, ended with a fizz Newsletter Article 15 February 2013 Pages: 10 - 10
Monoclonal antibody treatment may redeem itself in bladder cancer Rachel Webber Newsletter Article 15 February 2013 Pages: 11 - 11
Further comparative trials of milnacipran in depression needed Newsletter Article 15 February 2013 Pages: 12 - 12
Clobazam effective in children with refractory epilepsy Newsletter Article 15 February 2013 Pages: 14 - 14
Carboplatin/etoposide combination in advanced NSCLC Newsletter Article 15 February 2013 Pages: 14 - 14
Molgramostim increases tolerable dose of mitoxantrone Newsletter Article 15 February 2013 Pages: 15 - 15
Significant response in schizophrenia with ritanserin Newsletter Article 15 February 2013 Pages: 16 - 16
Cladribine restores NK cell number and activity in hairy cell leukaemia Newsletter Article 15 February 2013 Pages: 19 - 19
Cyclosporin chocolate wafer ‘flavour of the month’? Newsletter Article 15 February 2013 Pages: 19 - 19
Captopril shows antiarrhythmic potential - mechanism uncertain Newsletter Article 15 February 2013 Pages: 20 - 20